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PURPOSE
In children the assessment of solid tumors’ response to che-
motherapy is based primarily on size reduction, which can 
be unreliable and a late marker, in the presence of necrosis. 
We aimed to establish whether apparent diffusion coefficient 
(ADC) values of childhood neuroblastomas show proportion-
al changes in relation to chemotherapy response.
 
METHODS
We evaluated 15 pediatric patients with abdominopelvic 
neuroblastomas, who had undergone MRI before and after 
chemotherapy. Two radiologists retrospectively analyzed all 
images by drawing a round uniform region-of-interest in the 
solid/contrast-enhancing portion of the lesions in consensus. 
The ADC values from pre- and postchemotherapy images 
were compared. 
RESULTS
Postchemotherapy ADC values were significantly higher than 
those obtained before treatment (P < 0.05, for minimum, 
maximum, and median ADC values). 
CONCLUSION
Our results support diffusion-weighted MRI as a promising 
noninvasive biomarker of therapeutic responses. To the best 
of our knowledge, this is the first report to compare diffusion- 
weighted imaging findings before and after chemotherapy in 
childhood neuroblastic tumors.  
D iffusion-weighted (DW) magnetic resonance imaging (MRI) en-ables tracking of water molecules (Brownian motion) at a micro-scopic level. The use of different b values allows for the quantifi-
cation of signal loss in diffusion-sensitive sequences through apparent 
diffusion coefficient (ADC) maps. It has been shown that highly cellular 
areas with restricted diffusion demonstrate low ADC values compared 
to areas with less cellular content. Recent technological advances, in-
cluding echo-planar imaging, multichannel coils, and parallel imaging, 
allow for the usage of DW-MRI beyond neurological applications (1–5). 
The ADC values of malignant masses are relatively lower than those 
of benign masses, although overlapping ADC values of malignant and 
benign lesions have also been reported (1, 6–12). Currently, in children 
the assessment of solid tumors’ response to chemotherapy is based on 
size reduction; but this method can be unreliable as a marker, as tumors 
that shrink substantially may still be composed mainly of malignant 
cells (13, 14). 
Here, we aimed to evaluate whether ADC values in viable portions 
of childhood neuroblastomas show any changes depending on tumor 
cellularity before and after chemotherapy. We hypothesized that an in-
crease in ADC values over the course of chemotherapy could be used as a 
noninvasive marker of therapy response. To the best of our knowledge, 
this is the first report to compare DW-MRI findings before and after che-
motherapy in childhood neuroblastic tumors.
Methods
Patients
We retrospectively screened pediatric patients who had neuroblastic 
tumors and received treatment at our hospital between January 2009 
and August 2013. We found 36 pediatric patients who underwent rou-
tine protocol-driven MRI assessment for solid tumors. Out of this group 
we acquired data from children who had intra-abdominal neuroblastic 
tumors that were diagnosed histopathologically. Our institution gener-
ally prefers MRI over computed tomography; however, due to capacity 
and time restrictions, not all patients undergo MRI both at primary di-
agnosis and at postchemotherapy follow-up. Only those patients who 
underwent MRI before and after chemotherapy were included in this 
study. In addition, exclusion criteria included any oncological (chemo-
therapy or radiotherapy) or surgical treatment before initial imaging. 
Consequently, we evaluated 15 patients between 4–138 months of age 
(mean, 37.8 months) including five females and 10 males. Thirteen pa-
tients were Stage 4 and two patients were Stage 3. The timing of scans 
was determined by our pediatric oncology department and all patients 
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in this group received chemothera-
py according to relevant oncological 
treatment protocols. The lesions be-
came calcified, totally hemorrhagic, or 
necrotic in four patients after chemo-
therapy and we could not obtain ac-
ceptable ADC values for these lesions. 
Thus, we compared pre- and postche-
motherapy ADC values of 11 patients.
This study was approved by the Insti-
tutional Review Board of our university 
hospital (Project no:K12/121) and sup-
ported by the university research fund.
DW-MRI technique
The MRI examinations were per-
formed on one of two Siemens 1.5 T 
MRI scanners (Symphony or Avan-
to, Siemens Healthcare) with a body 
or head-neck coil (depending on the 
child’s body size). Children under sev-
en years of age were sedated prior to 
the scan without intubation following 
an anesthesiological safety assessment 
that adhered to our institutional poli-
cies. All patients had peripheral or cen-
tral venous access. Our routine abdom-
inal MRI protocol included axial and 
coronal T2-weighted turbo spin echo 
(TSE) sequence (repetition time/echo 
time (TR/TE), 4000/103; slice thick-
ness, 5 mm; number of excitations, 
1; TSE factor, 29), precontrast axial 
and coronal T1-weighted fast low-an-
gle shot (FLASH) sequence (TR/TE, 
127/3.52; flip angle, 70°; slice thick-
ness, 5 mm; number of excitations, 1), 
axial fat saturated T2-weighted TSE se-
quence (TR/TE, 4400/103; slice thick-
ness, 5 mm; number of excitations, 1; 
TSE factor, 29), axial in-phase/out-of-
phase imaging (TR/TE, 100/2.38–4.89; 
slice thickness, 5 mm; flip angle, 70°; 
number of excitations, 1), coronal 
true fast imaging with steady-state-
free precession (3D true FISP)(TR/TE= 
3.79/1.57; slice thickness, 5 mm; num-
ber of excitations, 1) sequences, and 
contrast-enhanced axial and coronal 
T1-weighted sequences following a 
bolus injection of 0.2 mmol/kg of me-
glumine gadoterate (Dotarem). Respi-
ratory triggering was used for children 
who were not capable of holding their 
breath. The mean time of the conven-
tional MRI examination was approxi-
mately 30 min.
DW-MRI was performed before con-
trast medium administration and a 
fat-saturated pulse was used to exclude 
severe chemical shift artifacts. Images 
were obtained in the axial plane us-
ing non-breath-hold, single-shot spin-
echo sequencing with the following 
image parameters: TR/TE, 4600/88; 
slice thickness, 5 mm; intersection gap, 
1 mm; echo-planar readout matrix, 
192×113; bandwidth, 1736 Hz/pixel. 
Four DW sequences were acquired to 
use signal averaging with b values of 
0, 200, 600, 800, and 1000 s/mm2, and 
isotropic images were generated on a 
pixel-by-pixel basis. ADC maps were 
created automatically. The mean time 
of the DW-MRI examination was ap-
proximately 5 min.
Image analysis 
All images were analyzed retrospec-
tively by two radiologists, one with six 
years of experience in pediatric imag-
ing (S.D.) and a second with five years 
of experience in abdominal imaging 
(N.A.), using the Advantage Worksta-
tion 4.4 (GE Healthcare). We did not 
attempt masking because it was notice-
able on the images whether they had 
been acquired before or after chemo-
therapy. Two readers reviewed the im-
ages in consensus and ADC measure-
ments were made by drawing a round, 
25 mm² region-of-interest (ROI). All 
ROIs for each lesion were placed over 
the solid/contrast-enhancing portion 
of the lesion at different slices through 
the tumor, which had apparent dif-
fusion-restriction visually on the DW 
images. Exclusion of necrotic areas was 
based on T2- and contrast-enhanced 
T1-weighted images (Fig. 1). The ADC 
measurements were repeated five times 
at different sites and averaged. The 
same procedure was repeated using the 
images acquired after the chemother-
apy and pre- and postchemotherapy 
images were compared. The duration 
between the examinations was 4–8 
months (mean, 4.8 months). In the 
pre- and postchemotherapy series, the 
ROIs were not at the same exact sites 
due to volume decreases. Examples of 
ROIs drawn on pre- and postchemo-
therapy ADC map images of a right 
adrenal neuroblastoma are shown in 
Fig. 2. 
We also measured the widest axial 
and craniocaudal diameters of the le-
sions on the images before and after 
chemotherapy and calculated the tu-
mor volumes using the ellipsoid for-
mula: length×breadth×depth×0.479.
Histopathology
Our consultant histopathologist 
(N.E.K., five years of experience with 
pediatric tumor histopathology) who 
was blinded to the MRI findings, re-
viewed histological slices from surgi-
cally resected tumors and graded their 
chemotherapy-induced changes as 
minimal, good, or marked according 
to current practice, considering the 
Figure 1. a–c. Axial T2-weighted (a), precontrast (b), and postcontrast (c) T1-weighted images showing the solid portion of a left-sided 
paravertebral ganglioneuroblastoma (arrow).  
a b c
percentage of necrosis, fibrosis, and 
calcification that they have (13). In 
addition, slices were graded according 
to their cellularity (low, 300 cells per 
high power fields [HPF]; intermediate, 
300–600 cells per HPF; high, 600 cells 
per HPF; intermixed, variable cellular-
ity) (15).
Three postchemotherapy specimens 
were obtained with tru-cut biopsy and 
excluded from this assessment. One 
patient was operated at another in-
stitution after chemotherapy and we 
could not evaluate the specimen. Pre-
chemotherapy specimens were mostly 
obtained with tru-cut or from bone 
marrow, so they were not subject to 
comparison with postchemotherapy 
specimens in terms of cellularity.
Statistical analysis
Statistical analysis was performed 
using the Statistical Package for Social 
Sciences version 17.0 (SPSS for Win-
dows, SPSS Inc.). Data were described 
as median because the continuous 
variables were not normally distribut-
ed (P > 0.05 in Kolmogorov-Smirnov 
test or Shapiro-Wilk, if n<30). Compar-
isons of not normally distributed data 
from pre- and postchemotherapy im-
ages were analyzed using the Wilcoxon 
test. P < 0.05 was considered statistical-
ly significant.
Results
We evaluated 15 pediatric patients 
(10 males and five females) with ab-
dominopelvic neuroblastic tumors, 
having 4–138 months of age (mean, 
37.8 months). Twelve of the lesions 
were located on an adrenal site and 
mostly accompanied by lymphade-
nopathy. Two patients had para-aor-
tic/paravertebral lesions. One lesion 
was located in the presacral region and 
was pathologically shown to be a gan-
glioneuroblastoma (Table 1). 
We could not obtain acceptable 
ADC values in four patients after che-
motherapy because the lesions became 
calcified, totally hemorrhagic, or ne-
crotic. We failed to find a contrast en-
hancing region to draw a ROI in these 
patients’ lesions. Thus, we compared 
the pre- and postchemotherapy ADC 
values of 11 patients. 
Before chemotherapy, the mean 
ADC values of the neuroblastomas and 
ganglioneuroblastomas in 15 patients 
ranged between 0.54×10-3 mm²/s and 
1.17×10-3 mm²/s (median, 0.74×10-3 
mm²/s). After chemotherapy, in 11 pa-
tients, the mean ADC values of the le-
sions ranged between 0.70×10-3 mm²/s 
and 1.25×10-3 mm²/s (median, 1.05×10-3 
mm²/s). Postchemotherapy ADC values 
in these 11 patients were significant-
ly higher than those obtained before 
treatment (P = 0.003). Table 1 sum-
marizes data on lesion location, histo-
pathological diagnosis, volume, pre- 
and postchemotherapy ADC values, 
and grading of chemotherapy-induced 
responses. Pre- and postchemotherapy 
ADC measurements of 11 patients is 
shown in Table 2. At the onset of our 
follow-up, the volume of the smallest 
lesion was 7 mL and the largest was 
1250 mL. After chemotherapy, the 
mean volume of all lesions decreased by 
88% (from 281.9 mL to 36.4 mL). There 
was no significant correlation between 
the size reduction of the lesions and the 
increase in the ADC values. Also, there 
was no significant relationship between 
the ADC values of the lesions after che-
motherapy and their cellularity rates 
after resection.
Discussion
In this study we found an increased 
distribution of ADC values after che-
motherapy in 11 patients. The me-
dian of the ADC values of all lesions 
increased from 0.74×10-3 mm²/s to 
1.05×10-3 mm²/s postchemotherapy. 
All lesions showed volume loss after 
chemotherapy except for the smallest 
lesion (patient 14), which showed no 
volume loss despite minimal increase 
in ADC value postchemotherapy. 
To the best of our knowledge, this 
is the first report to compare pre- and 
postchemotherapy DW-MRI findings 
in pediatric neuroblastic tumors. In 
2002, Uhl at al. (16) reported the first 
results on DW-MRI in neuroblastomas 
with correlations to histology. Since 
then, there have been few reports on 
DW-MRI for pediatric abdominal tu-
mors (7). Kocaoglu et al. (1) described 
31 abdominal masses, 15 of which 
were malignant, and proposed an ADC 
value of 1.1×10-3 mm²/s as a cutoff val-
ue to differentiate malignant from be-
nign masses. In 2011, McDonald et al. 
(13) reported a shift in the distribution 
of ADC patterns of pediatric abdomi-
nal tumors during chemotherapy. In 
the present study, we included a group 
of childhood neuroblastoma cases to 
investigate the correlation between 
chemotherapy response and reduction 
of diffusion restriction in neuroblastic 
tumors. In our series the increase in 
ADC values was not proportional to 
the volume loss of the tumors.
Humphries et al. (12) reported a cor-
relation between ADC value and tumor 
cellularity in pediatric patients. Preche-
motherapy specimens of our patients 
were mostly obtained with tru-cut or 
from bone marrow; thus, we could not 
evaluate the relationship between their 
cellularity and ADC values or compare 
them with postchemotherapy speci-
mens in terms of cellularity. We could 
not demonstrate a significant relation-
ship between the ADC values of the 
lesions after chemotherapy and their 
cellularity rates after resection. The ADC 
increase after chemotherapy seemed to 
be proportional with the rate of che-
motherapy-induced histopathological 
changes, but the patient numbers were 
not adequate to prove a statistically sig-
nificant relation. We accept that this is 
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Figure 2. a, b. An example of a region-of-interest drawn on an ADC map of a 
ganglioneuroblastoma before (a) and after chemotherapy (b). The mean ADC values were 
measured as 0.95×10-3 mm2/s and 1.42×10-3 mm2/s, respectively.
a b
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a feasibility study with a relatively small 
number of observations. As indicated in 
previous studies, our findings suggest a 
correlation between ADC distribution 
and biological response to chemothera-
py (12,13,17–21). 
Previous studies have shown that 
tumor shrinkage might be a delayed 
or insensitive marker (in case of par-
tial response) to evaluate chemother-
apy response; absence of reduction in 
tumor size does not necessarily mean 
no response (13, 14, 22). Particularly 
for solid, viable tumors, new methods 
are needed to histopathologically de-
tect a lack of chemotherapy response 
in a shrinking tumor or the degree 
of response in a growing tumor. We 
trust that our findings will contribute 
towards establishing a supplemental 
method for this purpose. 
In the literature, some investigators 
used large ROIs that included most 
solid parts of the lesions (6, 13); how-
ever, we preferred round, 25 mm2 ROIs 
placed around the solid/contrast-en-
hancing portion with restricted visu-
al diffusion, and averaged the results 
which, we believe, is a good method 
to exclude cystic parts, vessels, normal 
parenchyma, and areas with unclear 
intensities due to calcification or mo-
tion artifacts. 
Table 1. Summary of patient history and pre- and postchemotherapy findings by MRI and histopathology  
                                       Prechemotherapy                                             Postchemotherapy   
  Age   Mean and range  Mean and range Interval between 
Patient (months)/ Diagnosis/ Mass volume of ADC Mass volume of ADC exams Histopathologic  
no. gender location (mL) (×10-3 mm2/s) (mL) (×10-3 mm2/s) (months) response
1 46/M Neuroblastoma/ 105 0.84 (0.68–1.03) 10 (Necrotic) 5 Marked 
  left adrenal 
2 19/F Neuroblastoma/ 490 0.74 (0.62–0.91) 33 1.05 (0.80–1.33) 6 Good 
  right adrenal 
3 18/F Neuroblastoma/ 1250 0.71 (0.60–0.92) 44 0.80 (0.71–0.92) 8 Minimal 
  left adrenal 
4 25/M Ganglioneuroblastoma/  45 0.78 (0.71–0.86) 9 0.86 (0.77–0.99) 5 Minimal 
  left adrenal 
5 34/M Neuroblastoma/ 478 0.61 (0.49–0.76) 12 0.70 (0.65–0.75) 4 Good 
  right adrenal 
6 11/M Neuroblastoma/ 345 0.72 (0.66–0.81) 26 1.09 (1.01–1.22) 4 Tru-cut 
  para-aortic 
7 62/M Ganglioneuroblastoma/  150 0.54 (0.47–0.60) 40 1.25 (1.12–1.36) 5 N/A 
  left adrenal       
8 138/F Ganglioneuroblastoma/ 182 0.72 (0.66–0.77) 90 0.81 (0.74–0.93) 5 Minimal 
  presacral 
9 40/M Neuroblastoma/left  140 0.60 (0.51–0.71) 10 (Hemorrhagic) 4 Marked 
  adrenal-para-aortic 
10 96/M Neuroblastoma/ 460 0.87 (0.70–1.01) 70 0.95 (0.83–1.02) 5 Minimal 
  left adrenal 
11 4/M Neuroblastoma/ 15 1.17 (0.87–1.52) 8 (Hemorrhagic 5 Marked 
  left adrenal    and calcified)
12 12/F Neuroblastoma/ 286 0.79 (0.64–0.97) 78 (Necrotic 5 Tru-cut 
  right adrenal    and calcified)
13 5/M Neuroblastoma/ 78 0.58 (0.54–0.64) 12 1.13 (1.04–1.23) 3 Marked 
  right adrenal 
14 31/M Neuroblastoma/ 7 1.14 (1.12–1.21) 7 1.21 (0.96–1.35) 4 Tru-cut 
  right adrenal 
15 26/F Ganglioneuroblastoma/ 198 0.79 (0.74–0.85) 98 1.20 (1.06–1.29) 4 Good 
  paravertebral 
Mean  37.8  281.9 0.77 (±0.18) 36.4 1.00 (±0.19) 4.8
(±SD)  
ADC, apparent diffusion coefficient; M, male; F, female; N/A, not available (no postchemotherapy specimen); SD, standard deviation.
Table 2. Comparison of pre- and postchemotherapy ADC measurements of 11 patients
ADC Median Min–max
Prechemotherapy 0.74 0.54–1.17
Postchemotherapy 1.05 0.70–1.25
P = 0.003.
ADC, apparent diffusion coefficient.
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There were some limitations to this 
study. First, the long intervals between 
pre- and post-treatment MRI investi-
gations prevented us from concluding 
precisely that chemotherapy is the only 
factor causing the increase in ADC val-
ues. Second, we could not differentiate 
ganglioneuroblastomas from neuro-
blastomas, based on ADC values before 
or after chemotherapy, because of the 
insufficient number of ganglioneuro-
blastoma cases. Gahr et al. (6) also re-
ported that ADC values are related to 
the histopathological aspect of a tumor 
but cannot be used to differentiate a 
neuroblastoma from a ganglioneuro-
blastoma/ganglioneuroma yet. 
In conclusion, our results support the 
opinion that ADC values change after 
chemotherapy and can provide promis-
ing evidence to assess chemotherapy re-
sponse in pediatric neuroblastic tumors. 
We observed increased ADC values in 
viable parts of childhood abdominal 
neuroblastomas after chemotherapy. If 
verified in larger series, DW-MRI may 
be a promising noninvasive biomarker 
and can aid in the assessment of thera-
peutic responses. 
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